HER2 mutation status in Japanese HER2-positive breast cancer patients
暂无分享,去创建一个
Yu Dong | Tatsuya Toyama | N. Kondo | Satoru Takahashi | T. Toyama | Hiroyuki Kato | Yu Dong | Ryoichi Nakanishi | Satoru Takahashi | Naoto Kondo | Y. Endo | Yumi Endo | Nobuyasu Yoshimoto | Tomoko Asano | Yukari Hato | Mayumi Nishimoto | Hiroyuki Kato | R. Nakanishi | N. Yoshimoto | Tomoko Asano | Y. Hato | M. Nishimoto
[1] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[2] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[3] A. Sivachenko,et al. Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.
[4] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[5] A. Børresen-Dale,et al. The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.
[6] C. Sotiriou,et al. Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer , 2013, Journal of the National Cancer Institute.
[7] Ryan D. Morin,et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.
[8] Z. Keidar,et al. Treatment of metastatic extramammary Paget's disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F. , 2014, The oncologist.
[9] D. Allred,et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[10] Irmtraud M. Meyer,et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.
[11] Satoru Takahashi,et al. HER2 mutation status in Japanese HER2-negative breast cancer patients. , 2014, Japanese journal of clinical oncology.
[12] W. Park,et al. Somatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal, and Breast Carcinomas , 2006, Clinical Cancer Research.
[13] J. Thigpen,et al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer , 2012 .
[14] Li Ding,et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.
[15] Wendy Winckler,et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2 , 2012, Proceedings of the National Academy of Sciences.
[16] Jonathan W. Pillow,et al. POSTER PRESENTATION Open Access , 2013 .
[17] H. Iwata,et al. Clinical significance of the expression of estrogen receptors α and β for endocrine therapy of breast cancer , 2003, Cancer Chemotherapy and Pharmacology.
[18] James X. Sun,et al. Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations , 2013, Clinical Cancer Research.
[19] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[20] J. Reis-Filho,et al. Activating mutations in HER2: neu opportunities and neu challenges. , 2013, Cancer discovery.
[21] Gianluca Bontempi,et al. Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.
[22] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[23] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.